anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: Pioglitazone
Trial phase: Not Applicable
ATC code: A10BD05 | A10BD06 | A10BD09 | A10BD12 | A10BG03
SMILES: CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1
Sex: Female
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 32
Group description: Administration of pioglitazone to upper- and lower-body obese women

Pioglitazone: 30mg per day for four months
Eligibility criteria:
Inclusion Criteria:

You are a pre-menopausal woman between 18-40 years of age
Your Body Mass Index (BMI, weight-to-height2 ratio) is 27 - 38 kg/m2, inclusive
The ratio of your waist-to-hip circumferences is either >0.84 ("apple"-type body shape) or <0.77 ("pear"-type body shape)
You are willing to undergo a drug intervention for 16 weeks
You are willing to drink heavy water [similar to the ordinary water that is highly enriched in the naturally occurring stable (non-radioactive) form of hydrogen, deuterium; also called deuterium-labeled water] for 8 weeks before the beginning and during the second half of the drug intervention; you will need 24-hours access to a refrigerator for storage of the water.
You agree to use a double barrier method as a form of birth control to prevent pregnancy. Oral contraceptives (birth control pills) are not allowed in the study. Acceptable methods of birth control are condoms, spermicide, IUD (intrauterine device, must be hormone free - see list in clinic), diaphragm and abstinence. An example of a double barrier method would be condoms plus spermicide, etc.

Exclusion Criteria:

You have gained or lost more than 4.5 lb (2 kg) in the last 3 months
You have had significant changes in the diet or level of physical activity within the past month
You have a blood sugar of greater than 100 or a diagnosis of diabetes.
You have abnormal liver enzyme values from your blood work
You have a history of heart, kidney, lung, liver, and thyroid disease
You have an average blood pressure >140/90 at your screening visit
Have you had a positive test for human immunodeficiency virus (HIV), hepatitis B or hepatitis C?
You require chronic use of medications including diuretics, steroids, thyroid hormones, and adrenergic-stimulating agents (bronchodilators, nasal decongestants)
Intervention: Morphine
Trial phase: Not Applicable
ATC code: A07DA52 | N02AA01 | N02AA51 | N02AG01
SMILES: [H][C@@]12C=C[C@H](O)[C@]3([H])Oc4c(O)ccc5c4[C@]13CCN(C)[C@]2([H])C5
Sex: All
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 20
Group description: Morphine Sulfate: 15mg sustained release morphine sulfate, with a maximum dose of 120mg. Patients will be titrated up to a maximum dose of 8 pills a day for one month.
Eligibility criteria:
Inclusion Criteria:

18-60 years old
Healthy volunteer
Not allergic to remifentanil

Exclusion Criteria:

Patients younger than 18 or older than 70
Patients unwilling or unable to follow study instructions
Patients who don't speak English
Patients who are taking prescription opioid medications (e.g. vicodin, percocet) or are unwilling to refrain from taking anti-inflammatory medications such as Advil or Naproxen during 2 weeks prior to and during the 1 month study
Intervention: LATANOPROSTENE BUNOD
Trial phase: Phase 3
ATC code: S01EE06
SMILES: O=C(CCC/C=C\C[C@@H]1[C@@H](CC[C@@H](O)CCc2ccccc2)[C@H](O)C[C@@H]1O)OCCCCO[N+](=O)[O-]
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 283
Group description: BOL-303259-X ophthalmic solution QD (PM) and vehicle QD (AM) administered for 3 months into the study eye during the efficacy phase.
Eligibility criteria:
Inclusion Criteria:

Participants must have a diagnosis of OAG (including pigmentary or pseudoexfoliative) or OHT in 1 or both eyes.
Participants must meet the following IOP requirements at Visit 3
mean/median IOP ≥ 24 mmHg at a minimum of 2 time points in the same eye
IOP ≤ 36 mmHg at all 3 measurement time points in both eyes.
Participants with a best-corrected visual acuity (BCVA), using the Early Treatment of Diabetic Retinopathy Study (ETDRS) protocol, of +0.7 logMAR units (Snellen equivalent of approximately 20/100) or better in either eye.

Exclusion Criteria:

Participants with known hypersensitivity or contraindications to latanoprost, NO treatment, timolol maleate, other beta-adrenergic receptor antagonists or any of the ingredients in the study drugs.
Participants with a central corneal thickness greater than 600 μm in either eye.
Participants with advanced glaucoma and participants with a cup/disc ratio greater than 0.8 or a history of split fixation, or a field loss threatening fixation in either eye.
Participants who do not have an intact posterior capsule in either eye .
Participants with aphakia in either eye.
Participants with previous or active corneal disease in either eye.
Participants with current or a history of severe dry eye in either eye.
Participants with current or a history of optic disc hemorrhage in either eye.
Participants with current or a history of central/branch retinal vein or artery occlusion in either eye.
Participants with current or a history of macular edema in either eye.
Participants with very narrow angles (3 quadrants with less than Grade 2 according to Shaffer's anterior chamber angle grading system) and Participants with angle closure,congenital, and secondary glaucoma, and participants with history of angle closure in either eye.
Participants with a diagnosis of a clinically significant or progressive retinal disease in either eye.
Participants with any intraocular infection or inflammation in either eye within 3 months(90 days) prior to Visit 1 (Screening).
Participants with a history of ocular laser surgery in either eye within the 3 months(90 days) prior to Visit 1 (Screening).
Participants with a history of incisional ocular surgery or severe trauma in either eye within 3 months (90 days) prior to Visit 1 (Screening).
Intervention: LATANOPROSTENE BUNOD
Trial phase: Phase 3
ATC code: S01EE06
SMILES: O=C(CCC/C=C\C[C@@H]1[C@@H](CC[C@@H](O)CCc2ccccc2)[C@H](O)C[C@@H]1O)OCCCCO[N+](=O)[O-]
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 279
Group description: BOL-303259-X ophthalmic solution QD (PM) and vehicle QD (AM) administered for 3 months into the study eye during the efficacy phase
Eligibility criteria:
Inclusion Criteria:

Participants must have a diagnosis of OAG (including pigmentary or pseudoexfoliative) or OHT in 1 or both eyes.
Participants must meet the following IOP requirements at Visit 3
mean/median IOP ≥ 24 mmHg at a minimum of 2 time points in the same eye
IOP ≤ 36 mmHg at all 3 measurement time points in both eyes.
Participants with a best-corrected visual acuity (BCVA), using the Early Treatment of Diabetic Retinopathy Study (ETDRS) protocol, of +0.7 logMAR units (Snellen equivalent of approximately 20/100) or better in either eye.

Exclusion Criteria:

Participants with known hypersensitivity or contraindications to latanoprost, NO treatment, timolol maleate, other beta-adrenergic receptor antagonists or any of the ingredients in the study drugs.
Participants with a central corneal thickness greater than 600 μm in either eye.
Participants with advanced glaucoma and participants with a cup/disc ratio greater than 0.8 or a history of split fixation, or a field loss threatening fixation in either eye.
Participants who do not have an intact posterior capsule in either eye .
Participants with aphakia in either eye.
Participants with previous or active corneal disease in either eye.
Participants with current or a history of severe dry eye in either eye.
Participants with current or a history of optic disc hemorrhage in either eye.
Participants with current or a history of central/branch retinal vein or artery occlusion in either eye.
Participants with current or a history of macular edema in either eye.
Participants with very narrow angles (3 quadrants with less than Grade 2 according to Shaffer's anterior chamber angle grading system) and participants with angle closure,congenital, and secondary glaucoma, and participants with history of angle closure in either eye.
Participants with a diagnosis of a clinically significant or progressive retinal disease in either eye.
Participants with any intraocular infection or inflammation in either eye within 3 months(90 days) prior to Visit 1 (Screening).
Participants with a history of ocular laser surgery in either eye within the 3 months(90 days) prior to Visit 1 (Screening).
Participants with a history of incisional ocular surgery or severe trauma in either eye within 3 months (90 days) prior to Visit 1 (Screening).
Intervention: Betaine
Trial phase: Phase 4
ATC code: A09AB02 | A16AA06
SMILES: C[N+](C)(C)CC(=O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 15
Group description: Betaine 1000 mg by mouth daily

Betaine
Eligibility criteria:
Inclusion Criteria:

Age 20-65
Absence of all exclusion criteria

Exclusion Criteria:

women who are currently pregnant at the time of recruitment and/or plan to become pregnant within 2 months
individuals taking nutritional supplements at the time of recruitment
individuals who have taken nutritional supplements within the last 3 months
participants enrolled in any other clinical trial
women who are currently breastfeeding
individuals known to have coronary heart disease, cerebrovascular disease, hypertension, renal disease, chronic obstructive pulmonary disease, asthma, cancer, or liver disease
participants with protein or glucose in their urine sample (dipstick test)
individuals whose drinking water history is complete for < 3 months
Intervention: Chlorthalidone
Trial phase: Phase 4
ATC code: C03BA04 | C03BB04 | C03EA06 | G01AE10
SMILES: NS(=O)(=O)c1cc(C2(O)NC(=O)c3ccccc32)ccc1Cl
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 14
Group description: Open-label, forced-titration of Chlorthalidone (25mg/day at baseline)
Eligibility criteria:
Inclusion Criteria:

Age greater than 18 years.
Estimated glomerular filtration rate (eGFR) ≤ 45 ml/min/1.73m2 but ≥20 mL/min/1.73m2.
Poorly controlled blood pressure by 24-hour ambulatory blood pressure (BP) monitoring.
Treated hypertension: use of at least one antihypertensive drug. One of the drugs should be either an angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB). If these are contraindicated then use of a beta-blocker is required.

Exclusion Criteria:

Use of thiazide or thiazide-like drugs in the previous 3 months.
Use of furosemide in a dose >200 mg/d.
Ambulatory BP of either ≥160 systolic or ≥100 mmHg by 24-hour ambulatory BP monitoring.
Expected to receive renal replacement therapy within the next 3 months.
Vascular event such as myocardial infarction, heart failure hospitalization, or stroke within 3 months prior to randomization.
Pregnant or breastfeeding women or women who are planning to become pregnant or those not using a reliable form of contraception (oral contraceptives. condoms and diaphragms will be considered reliable).
Known hypersensitivity to thiazide or sulfa drugs.
Organ transplant recipient or therapy with immunosuppressive agents. Nasal or inhaled corticosteroids will be permitted.
Intervention: Acetyl hexapeptide-3
Trial phase: Phase 2
SMILES: C=C(N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)[C@H](CCC(=O)O)NC(C)=O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 3
Group description: Participants in the 0.05% AH-8 arm received the higher dose of the study drug, Acetyl Hexapeptide 8 (AH-8), which is sold under the band name, Argireline.

Topical acetyl hexapeptide-8
Eligibility criteria:
INCLUSION CRITERIA:
Primary blepharospasm diagnosed or confirmed by a Movement Disorders Neurologist, confirmed at the initial visit by a study investigator.

Individuals off BoNT therapy for at least 4 months will be eligible for this study.

Severity prompting need for treatment as determined by clinical judgment
At least a score of 4 on the JBRS
At least a score of 8 on the BDS
Duration of symptoms of at least 1 year, without subjective active progression by patient report
Concomitant therapy allowed, except injectable BoNT therapy, provided the doses remain stable throughout the study period
Adult patients (> 18)

EXCLUSION CRITERIA:

Blepharospasm associated with generalized or extensive regional dystonia
Medical condition impairing the patient's ability to comply with the study protocol or to perform daily applications of the cream as instructed as judged by recruiting physician
Local eyelid pathology precluding topical treatment
Received BoNT within 4 months prior to enrollment
Continued benefit from a prior BoNT injection (by history and self assesment) Current use of cosmetic wrinkle creams
Prior myectomy procedure excluded
Pregnant women excluded. Barrier contraception will be used throughout the study for women of childbearing age, as it is not known how the use of hormonal contraceptives may interact with the study substance. Menopausal status will be determined by the CNS IRB criteria. In women of childbearing potential, a pregnancy test will be performed at the initial visit and periodically every 2 months for the duration of the study. Barrier contraception will be deemed necessary for the duration of the study and none after.
Use of other treatments for blepharospasm allowed if the doses remain constant
Allergy/sensitivity to study substance or vehicle.
Active drug or alcohol abuse or dependence
Patients with uncontrolled co-existing medical conditions: uncontrolled systemic hypertension with values above 170/100; active heart disease needing immediate intervention; active respiratory disease needing intervention; known or observed eye pathology; any condition that would render the patient unable to safely cooperate with the study tests as judged by the screening physician
Cognitive inability to independently use cr(SqrRoot)(Registered Trademark)me use safely.
Intervention: Acetyl hexapeptide-3
Trial phase: Phase 2
SMILES: C=C(N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)[C@H](CCC(=O)O)NC(C)=O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 2
Group description: Participants in the 0.025% AH-8 arm received the lower dose of the study drug, Acetyl Hexapeptide 8 (AH-8), which is sold under the band name, Argireline.

Topical acetyl hexapeptide-8
Eligibility criteria:
INCLUSION CRITERIA:
Primary blepharospasm diagnosed or confirmed by a Movement Disorders Neurologist, confirmed at the initial visit by a study investigator.

Individuals off BoNT therapy for at least 4 months will be eligible for this study.

Severity prompting need for treatment as determined by clinical judgment
At least a score of 4 on the JBRS
At least a score of 8 on the BDS
Duration of symptoms of at least 1 year, without subjective active progression by patient report
Concomitant therapy allowed, except injectable BoNT therapy, provided the doses remain stable throughout the study period
Adult patients (> 18)

EXCLUSION CRITERIA:

Blepharospasm associated with generalized or extensive regional dystonia
Medical condition impairing the patient's ability to comply with the study protocol or to perform daily applications of the cream as instructed as judged by recruiting physician
Local eyelid pathology precluding topical treatment
Received BoNT within 4 months prior to enrollment
Continued benefit from a prior BoNT injection (by history and self assesment) Current use of cosmetic wrinkle creams
Prior myectomy procedure excluded
Pregnant women excluded. Barrier contraception will be used throughout the study for women of childbearing age, as it is not known how the use of hormonal contraceptives may interact with the study substance. Menopausal status will be determined by the CNS IRB criteria. In women of childbearing potential, a pregnancy test will be performed at the initial visit and periodically every 2 months for the duration of the study. Barrier contraception will be deemed necessary for the duration of the study and none after.
Use of other treatments for blepharospasm allowed if the doses remain constant
Allergy/sensitivity to study substance or vehicle.
Active drug or alcohol abuse or dependence
Patients with uncontrolled co-existing medical conditions: uncontrolled systemic hypertension with values above 170/100; active heart disease needing immediate intervention; active respiratory disease needing intervention; known or observed eye pathology; any condition that would render the patient unable to safely cooperate with the study tests as judged by the screening physician
Cognitive inability to independently use cr(SqrRoot)(Registered Trademark)me use safely.
Intervention: Caffeine Citrate
Trial phase: Not Applicable
SMILES: Cn1c(=O)c2c(ncn2C)n(C)c1=O.O=C(O)CC(O)(CC(=O)O)C(=O)O
Sex: All
Age groups: Child
Healthy volunteers: No
Participants at risk: 41
Group description: Subjects randomized to this arm will receive blinded Caffeine citrate.

Caffeine citrate: Enrolled subjects will be randomized to receive a study drug consisting of either blinded Caffeine citrate.

Randomization and study drug preparation will be done by the NICU pharmacy. Investigators and clinicians will be blinded to the assigned drug.

After randomization, an initial loading dose of 20 mg/Kg of study drug will be followed by a 5 mg/Kg/day maintenance dose. The assigned study drug will be administered intravenous or orally as determined by the clinical team.

Infants will continue to receive the study drug until 12 hours prior to the first elective extubation.
Eligibility criteria:
Inclusion Criteria:

Premature neonates born between 23 and 30 completed weeks of gestation.
Requiring mechanical ventilation within the first 5 postnatal days
Written-informed parental consent for the study

Exclusion Criteria:

Major congenital anomalies
Small for gestational age
Intervention: Ecopipam
Trial phase: Phase 3
SMILES: [H][C@@]12c3cc(O)c(Cl)cc3CCN(C)[C@@]1([H])CCc1ccccc12
Sex: All
Age groups: Child | Adult | Older Adult
Healthy volunteers: No
Participants at risk: 9
Group description: Active substance being tested, orally once a day at bedtime

Ecopipam: Antagonist of the dopamine D1 receptor
Eligibility criteria:
Inclusion Criteria:

Subjects must have classic LND as defined by (a) characteristic clinical syndrome (evidence of overproduction of uric acid, severe generalized dystonia, frequent and persistent self-injurious behavior (SIB), and cognitive impairment) and (b) laboratory confirmation for mutation of the HPRT gene or severe deficiency of the associated enzyme.
Subjects must have a minimum combined score of 20 on the Behavior Problems Inventory (BPI) SIB subscales for frequency and severity as assessed by the caregiver.
Subjects must have a minimum score of 4 on the Physician's Global Impression (PGI) severity scale.
Subject must be ≥ 6 years old.
Subjects must weigh > 10 kg.

Exclusion Criteria:

Subjects who are currently treated with medications for seizures.
Subjects who are on neuroleptics or dopamine-depleting agents.
Subjects with impaired renal function as defined by a serum creatinine >1.5 mg/dL.
Intervention: AUY922
Trial phase: Phase 2
SMILES: CCNC(=O)c1noc(-c2cc(C(C)(C)C)c(O)cc2O)c1-c1ccc(CN2CCOCC2)cc1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 6
Group description: Via intravenous infusion on Days 1, 8 and 15 of each 21 day cycle (once per week). Infusion lasts approximately 60 minutes
Eligibility criteria:
Inclusion Criteria:

Histologically or cytologically confirmed advanced NSCLC
Tumor characterized by abnormalities in ALK
Required to provide archival tissue in the form of 5 formalin fixed paraffin embedded sections
Have acquired resistance to treatment with an ALK-TKI
At least one measurable lesion as defined by RECIST criteria
Life expectancy of at least 12 weeks

Exclusion Criteria:

Pregnant or breastfeeding
Discontinued ALK TKI more than four weeks prior to enrollment
Unresolved diarrhea greater than or equal to CTCAE grade 1
Not willing to use double barrier methods of contraception
Prior anti-neoplastic treatment with any HSP90 or HDAC inhibitor compound
Have received cytoxic chemotherapy in the intervening period since discontinuation of an ALK-TKI
Have undergone major surgery within 2 weeks prior to starting study drug
Any concurrent or uncontrolled illness
Any known disorders due to a deficiency in bilirubin glucuronidation
Taking therapeutic doses of warfarin
Any serious cardiac disorders or abnormalities
Concurrent malignancies or invasive cancers diagnosed within the past 2 years except for adequately treated basal cell cancer of the skin or in situ cancers
Known to be HIV positive
Known hypersensitivity to any of the study drugs or their excipients
Participation in another clinical study within 30 days before the first study treatment
Intervention: Fenofibrate
Trial phase: Not Applicable
ATC code: C10AB05 | C10BA03 | C10BA04 | C10BA09 | C10BA12
SMILES: CC(C)OC(=O)C(C)(C)Oc1ccc(C(=O)c2ccc(Cl)cc2)cc1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 34
Group description: Participants were instructed to take one fenofibrate 160 mg capsule every day for 12 weeks

Fenofibrate
Eligibility criteria:
Inclusion Criteria:

Type 2 diabetes mellitus

Exclusion Criteria:

body weight > 300 lb.
HIV
hypothyroid
steroid medication, fenofibrate
smoking
BP > 140/90
heart disease
pregnant or lactating
consumption of > 5 alcoholic drinks/wk
creatinine > 1.5 mg/dL
hematocrit < 28
Intervention: Ganaplacide
Trial phase: Phase 2
SMILES: CC1(C)c2nc(-c3ccc(F)cc3)c(Nc3ccc(F)cc3)n2CCN1C(=O)CN
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 11
Group description: Participants with Plasmodium vivax malaria received KAF156 400 mg once a day for three days.
Eligibility criteria:
Inclusion Criteria:

-Male and female patients aged 20 to 60 years;Presence of mono-infection of P. falciparum or P. vivax; Weight between 40 kg to 90 kg.

Exclusion Criteria:

Patients with signs and symptoms of severe/complicated malaria
Infection with more than one parasite species
Women of child-bearing potential; pregnant or nursing women
Those who have taken any anti-malarial treatment in the preceding 14 days or other investigational drugs within 30 days or 5 half-lives
Intervention: Ganaplacide
Trial phase: Phase 2
SMILES: CC1(C)c2nc(-c3ccc(F)cc3)c(Nc3ccc(F)cc3)n2CCN1C(=O)CN
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 10
Group description: Participants with Plasmodium falciparum malaria received KAF156 400mg once a day for three days.
Eligibility criteria:
Inclusion Criteria:

-Male and female patients aged 20 to 60 years;Presence of mono-infection of P. falciparum or P. vivax; Weight between 40 kg to 90 kg.

Exclusion Criteria:

Patients with signs and symptoms of severe/complicated malaria
Infection with more than one parasite species
Women of child-bearing potential; pregnant or nursing women
Those who have taken any anti-malarial treatment in the preceding 14 days or other investigational drugs within 30 days or 5 half-lives
Intervention: Ganaplacide
Trial phase: Phase 2
SMILES: CC1(C)c2nc(-c3ccc(F)cc3)c(Nc3ccc(F)cc3)n2CCN1C(=O)CN
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 22
Group description: Participants with Plasmodium falciparum malaria received a single dose of KAF156 800mg.
Eligibility criteria:
Inclusion Criteria:

-Male and female patients aged 20 to 60 years;Presence of mono-infection of P. falciparum or P. vivax; Weight between 40 kg to 90 kg.

Exclusion Criteria:

Patients with signs and symptoms of severe/complicated malaria
Infection with more than one parasite species
Women of child-bearing potential; pregnant or nursing women
Those who have taken any anti-malarial treatment in the preceding 14 days or other investigational drugs within 30 days or 5 half-lives